Tiziana Life Sciences is trading at $0.96 (+5.45%) as of the July 28 session, extending a modest rebound from the prior day’s gains despite a lack of fresh company-specific catalysts.
- The move appears to be a stock-specific bounce, as the broader biotech sector remains under pressure with the XBI down 2.16%.
- General Nasdaq weakness continues to weigh on growth stocks, suggesting the current price action is driven more by risk sentiment than fundamental changes.